DrugPatentWatch Database Preview

Tolmar Therap Company Profile

« Back to Dashboard

What is the competitive landscape for TOLMAR THERAP, and when can generic versions of TOLMAR THERAP drugs launch?

TOLMAR THERAP has four approved drugs.

There are ten US patents protecting TOLMAR THERAP drugs.

There are sixty-seven patent family members on TOLMAR THERAP drugs in twenty-six countries.

Summary for Tolmar Therap

International Patents:	67
US Patents:	10
Tradenames:	1
Ingredients:	1
NDAs:	4

Drugs and US Patents for Tolmar Therap

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar Therap	ELIGARD	leuprolide acetate	INJECTABLE;SUBCUTANEOUS	021731-001	Dec 14, 2004		RX	Yes	Yes	9,914,802		Y	Y
Tolmar Therap	ELIGARD	leuprolide acetate	INJECTABLE;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes	8,470,359		Y	Y
Tolmar Therap	ELIGARD	leuprolide acetate	INJECTABLE;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes	9,283,282		Y	Y
Tolmar Therap	ELIGARD	leuprolide acetate	INJECTABLE;SUBCUTANEOUS	021379-001	Jul 24, 2002		RX	Yes	Yes	9,283,282		Y	Y

Expired US Patents for Tolmar Therap

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Tolmar Therap	ELIGARD	leuprolide acetate	INJECTABLE;SUBCUTANEOUS	021343-001	Jan 23, 2002	5,324,519
Tolmar Therap	ELIGARD	leuprolide acetate	INJECTABLE;SUBCUTANEOUS	021343-001	Jan 23, 2002	5,599,552
Tolmar Therap	ELIGARD	leuprolide acetate	INJECTABLE;SUBCUTANEOUS	021731-001	Dec 14, 2004	6,395,293
Tolmar Therap	ELIGARD	leuprolide acetate	INJECTABLE;SUBCUTANEOUS	021343-001	Jan 23, 2002	5,733,950

Non-Orange Book US Patents for Tolmar Therap

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,143,314	Controlled release liquid delivery compositions with low initial drug burst
6,630,155	Controlled release liquid delivery compositions with low initial drug burst

International Patents for Tolmar Therap Drugs

Country	Document Number	Estimated Expiration
Portugal	2158900
Japan	5969190
Germany	60111068
Canada	2436275

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Tolmar
• Tolmar Therap